Navigation Links
Gene-Eden-VIR Has Best Value; polyDNA Compares Treatments for HPV Infection
Date:4/29/2013

Rochester, NY (PRWEB) April 29, 2013

polyDNA recommends Gene-Eden-VIR as the most cost effective means of treating a latent HPV infection. During Money Smart Week (1), polyDNA is doing its part by contrasting the cost of HPV treatments. One of those treatments is Gene-Eden-VIR, a natural remedy against the latent HPV virus.

This week, the media, government agencies, not-for-profits, schools, financial institutions and businesses of all kinds are working together to help customers manage their personal finances better. To help customers who suffer from HPV infections, polyDNA compared the cost of Gardasil, Cervarix and Gene-Eden-VIR. The first two are FDA approved vaccines while the third is a natural, antiviral remedy.

“All my friends have been getting the HPV jab. But, I’ve been waiting it out. I’ve read some stuff online about the studies done on them, Gardasil for sure, only lasts for like…5 years. Then you know, it only protects against 4 strains and I read that there are more than 40 types that can infect the genitals, so for $390, it sounds like Gardasil’s protection is super limited.” -Irene D.

The only FDA drugs approved for HPV prevention are Gardasil and Cervarix. Both are vaccines. Gardasil protects against four HPV strains, and Cervarix protects against two. Neither vaccine is effective if someone is already infected with one of these HPV strains. (2)(3)

According to Cancer.org, the cost of Gardasil is $130 per dose, and it requires at least 3 doses for a person to be considered fully vaccinated. This means that the full cost of vaccination with Gardasil is $390.00. (4)

In 2011 the cost of Cervarix was lowered from $134.95 to $90.00 per dose. (5) However, even at $90.00 per dose, (again at 3 doses for full vaccination) Cervarix comes to a total of $270.00. That’s $120.00 less than Gardasil, but for some customers this cost is still significant.

Gene-Eden-VIR is an antiviral remedy that boosts the immune system against the latent HPV virus. A month’s supply of Gene-Eden-VIR is $37.99. That’s $232.01 cheaper than Cervarix, and well over $300 cheaper than Gardasil.

In addition, a post marketing clinical study, Gene-Eden-VIR was shown to be safe and highly effective against the latent HPV virus. Over 70% of Gene-Eden-VIR users reported a reduction in HPV symptoms. (6)

Gene-Eden-VIR is highly effective against the latent HPV virus, each ingredient was chosen through a scientific approach. Scientists scanned thousands of scientific and medical papers published in various medical and scientific journals around the world to identify the safest, most effective natural ingredients that target the latent form of HPV. (7)

To learn more about Gene-Eden-VIR, the only product on the market today that helps the body target the latent HPV virus and that is scientifically backed by published material, visit http://www.gene-eden-kill-virus.com.

References:

(1)    http://www.moneysmartweek.org/
(2)    http://www.gardasil.com/about-gardasil/about-gardasil/
(3)    http://us.gsk.com/html/medicines/index.html#vaccines
(4)http://www.cancer.org/cancer/cancercauses/othercarcinogens/infectiousagents/hpv/humanpapillomavirusandhpvvaccinesfaq/hpv-faq-vaccine-cost
(5)    http://sanevax.org/glaxosmithkline-drops-the-price-of-cervarix/
(6)    http://www.cbcd.net/Gene-Eden-VIR-Clinical-Study.php
(7)    gene-eden-kill-virus.com/studies.php

###

polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.

In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.

polyDNA developed Gene-Eden-VIR , an antiviral natural remedy that helps the immune system kill latent viruses.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10666360.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Gene-Eden-VIR is Most Cost Effective; polyDNA Compares Treatments for Herpes Infection
2. GYT and Take Gene-Eden-VIR; polyDNA Recommends an HPV Remedy to Infected Individuals
3. Newly-Published Study Compares SURFAXIN LS™ and CUROSURF® in Well-Established Model of Respiratory Distress Syndrome
4. Study Says Kidney Bean Leaves Work Against Bed Bugs, My Cleaning Products Compares Its With a Non-Pesticide Bed Bug Spray
5. Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response
6. LoneStar Heart Acquires Worldwide Exclusive Rights to New Class of Small Molecules That May Lead to New Treatments for Diabetes
7. Atlanta LASIK Surgeon Dr. Ashraf Releases YouTube Videos Featuring Patient Testimonials and Discussion of Common Eye Treatments
8. Lung Cancer Survivors Share Stories of Value of Early Detection and Hope for More Effective Treatments
9. Only 16% of Donations go to New Cancer Treatments in Some Charities. With cureLauncher, 91% of Contributions Go Directly to New Cures for Cancer.
10. CureLauncher is Described on LIVESTRONG Blog as Modern Platform That Gets People Involved in Advancing New Cancer Treatments
11. Bacterias hidden skill could pave way for stem cell treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), ... and plans to commercialize innovative therapeutics for patients ... stock were approved for trading on the OTCQX ... the OTCQX, effective today, under the ticker symbol ... market, companies must meet high financial standards, follow ...
(Date:12/8/2016)... , Dec. 8, 2016 Eutilex Co. ... billion KRW (US $18.9M) Series A financing. This financing ... G.N. Tech Venture and SNU Bio Angel. This new ... 30.5 billion KRW (US $27.7M) since its founding in ... to bolster the development and commercialization of its immuno-oncology ...
(Date:12/8/2016)... 2016   Biocept, Inc . (NASDAQ: ... clinically actionable liquid biopsy tests to improve the ... featuring its Target Selector™ Circulating Tumor Cell platform ... detection of actionable biomarkers in patients with metastatic ... Sara Cannon Research Institute (SCRI), the research arm ...
(Date:12/7/2016)... McLean, VA (PRWEB) , ... December 07, 2016 ... ... peer-reviewed medical journal has concluded that “in the setting of previously treated, advanced ... Further refinement in defining the optimal patient population and timing of blood sampling ...
Breaking Biology Technology:
(Date:11/14/2016)... 14, 2016  xG Technology, Inc. ("xG" or the ... wireless communications for use in challenging operating environments, announced ... 2016. Management will hold a conference call to discuss ... Eastern Time (details below). Key Recent Accomplishments ... million binding agreement to acquire Vislink Communication Systems. The ...
(Date:6/22/2016)... 2016  The American College of Medical Genetics and Genomics ... as one of the fastest-growing trade shows during the ... Bellagio in Las Vegas . ... growth in each of the following categories: net square feet ... of attendees. The 2015 ACMG Annual Meeting was ranked 23 ...
(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
Breaking Biology News(10 mins):